Biota Pharmaceuticals to Present at 28th Annual ROTH Conference
March 09 2016 - 7:46PM
Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a
biopharmaceutical company focused on the discovery and development
of direct-acting antivirals that address infections that have
limited therapeutic options, announced today that Biota’s CEO &
President Joseph Patti, PhD will present a corporate overview at
the 28th Annual ROTH Conference on Monday, March 14, 2016 at 12:00
p.m. PT in Dana Point, CA.
A live webcast of the presentation can be accessed under “Events
and Presentations” in the Investors section of the Company’s
website at www.biotapharma.com or at
http://wsw.com/webcast/roth30/bota.
A replay of the webcast will be archived for 30 days following
the presentation.
About Biota Pharmaceuticals,
Inc.
Biota Pharmaceuticals is focused on the
discovery and development of direct-acting antivirals to treat
infections that have limited therapeutic options and affect a
significant number of patients globally. The Company has three
product candidates in active clinical development: These include
vapendavir, an oral treatment for human rhinovirus infections in
moderate-to-severe asthmatics currently being evaluated in the
Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion
protein inhibitor in Phase 2 development for the treatment and
prevention of respiratory syncytial virus (RSV) infections and has
received Fast Track designation by the U.S. FDA; and BTA074, a
topical antiviral treatment in Phase 2 development for condyloma
caused by human papillomavirus types 6 & 11. For additional
information about the Company, please visit
www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals,
Inc.
Mark Colonnese
Executive Vice President and Chief Financial Officer
(678) 221-3381
m.colonnese@biotapharma.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024